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CD10 expression in urothelial bladder carcinomas: staining
patterns and relationship with pathologic parameters*
Nilüfer ONAK KANDEMİR1, Burak BAHADIR1, Banu DOĞAN GÜN1, Gamze YURDAKAN1,
Nimet KARADAYI2, Şükrü Oğuz ÖZDAMAR1
Aim: CD10 is a cell surface metalloprotease that inactivates various bioactive neuropeptides. CD10 has been suggested
as a useful prognostic marker for urothelial carcinoma, but there are only a few studies of CD10 in urothelial tumors and
they have shown varying results. The aims of this study were to investigate the expression of CD10 in urothelial bladder
carcinomas and to clarify its association with pathologic parameters.
Materials and methods: A total of 50 urothelial bladder carcinomas were selected from archival material. All cases were
reevaluated histopathologically and graded according to the WHO/ISUP 1998 classification. The TNM system was used
for their pathological staging. CD 10 immunohistochemical staining was performed on one representative tissue block
for each case.
Results: 35 of the 50 (70%) tumors showed positive CD10 immunostaining. We found a statistically significant difference
in terms of CD10 extent between low grade and high grade tumors. No association was detected between CD10
expression and other pathologic parameters. No relationship was found between CD10 expression and tumor size,
lymphovascular invasion, or pathological stage.
Conclusion: According to our findings, high grade carcinomas showed a wider CD10 expression than that in low grade
carcinomas. CD10 may play an important role in the progression and differentiation of bladder urothelial carcinomas.
Key words: Bladder, papillary urothelial carcinoma, CD10, immunohistochemistry

Ürotelyal mesane karsinomlarında CD10 Ekspresyonu: Boyanma paterni ve patolojik
parametreler ile ilişkisi
Amaç: CD10, çeşitli biyoaktif nöropeptitleri inaktive eden hücre yüzey metaloproteazıdır. CD10’un ürotelyal
karsinomlarda prognostik belirleyici olarak kullanılabileceği öne sürülmektedir. Ancak ürotelyal tümörlerde CD10
ekspresyonunu araştıran az sayıda çalışma bulunmaktadır ve sonuçları farklılıklar göstermektedir. Bu çalışmada, ürotelyal
mesane karsinomlarında CD10 ekspresyonu incelenmiş ve patolojik parametreler ile ilişkisi araştırılmıştır.
Yöntem ve gereç: Toplam 50 ürotelyal mesane karsinomu arşiv materyallerinden seçilmiştir. Tüm olgularda histopatolojik
bulgular tekrar gözden geçirilmiş ve WHO/ISUP 1998 sistemine göre derecelendirme uygulanmıştır. Patolojik evreleme
için TNM sistemi kullanılmıştır. Her olgu için seçilen bir temsili doku bloğuna CD10 için immünhistokimyasal boyama
işlemi gerçekleştirilmiştir.
Bulgular: Elli olgununun 35 (% 70)’inde CD10 ekspresyonu belirlendi. Çalışmamızda düşük ve yüksek dereceli ürotelyal
tümörler arasında CD10 immünreaktivitesinin yaygınlığı açısından istatistiksel olarak anlamlı farklılık belirlendi. CD10
ekspresyonu ile tümör boyutu, lenfovasküler invazyon varlığı ve patolojik evre arasında ilişki saptanmadı.
Sonuç: Bulgularımız, yüksek dereceli ürotelyal karsinomlarda, düşük dereceli karsinomlara göre daha yüksek oranda
CD10 ekspresyonu saptandığını göstermektedir. CD10 ürotelyal karsinomların progresyonunda ve diferansiyasyonunda
rol oynayabilir.
Anahtar sözcükler: Mesane, papiller ürotelyal karsinom, CD10, immünhistokimya
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Introduction
CD10 is a cell-surface metalloprotease that can
limit cellular responses to peptide hormones by
hydrolyzing them, reducing the concentration of
peptide available for receptor binding and signal
transduction. In addition to its enzymatic function,
the CD10 protein has a direct role in signal
transduction pathways that regulate cell growth and
apoptosis. Because of its structural similarity to the
matrix metalloproteases in the stroma, CD10 is
thought also to affect the invasion and metastatic
potential of tumor cells by altering the cellular
microenvironment (1-3). CD10 was initially
identified as a cell-surface antigen expressed by acute
lymphoblastic leukaemias, and hence its early
designation as CALLA. This antigen is widely used for
the categorization of acute leukaemias and for the
subclassification of malignant lymphomas (3-5).
Recently, several studies have reported CD10
expression in various non-hematolymphoid tumors
and in normal tissues (5-9).
Changes in CD10 activity have been demonstrated
to have different effects in different tumor types (59). CD10 expression inhibits the proliferation and
progression of tumor cells in prostate (10-11) and
lung cancers (12), stimulating apoptosis. In contrast,
increases in CD10 activity in colorectal carcinomas
(13), breast carcinomas (14), and malignant
melanomas (15) are associated with invasion and
metastasis.
To date, few studies have investigated CD10
expression in urinary bladder tissues. Whilst some
studies have not detected CD10 expression in
nonneoplastic urothelium (9), others have, albeit to a
lesser extent than in urothelial tumors (16-17). Its
expression has been reported to occur in 43%–67% of
urothelial neoplasms. Whilst in the majority of
reports, CD10 expression shows an inverse
correlation with tumor grade, a positive correlation
with grade has been noted in others (9, 16-18).
In this study, we investigated CD10 expression in
urothelial carcinomas by immunohistochemistry and
analyzed its relationship with pathological
parameters, such as tumor size, histologic grade,
pathologic stage, and lymphovascular invasion.
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Materials and methods
Patients
We randomly selected 50 patients with urinary
bladder urothelial carcinoma from pathology
archives. Of these, 46 were transurethral resections
(TUR) and 4 were radical cystectomies performed at
Zonguldak Karaelmas University, Faculty of Medicine
and Lutfi Kırdar Kartal Training and Research
Hospital, in 2005 and 2006. In addition, material from
10 cystoscopic biopsies, which was obtained in nonneoplastic disease and contained normal urothelial
mucosa, was included in the study for control
purposes. We obtained the patients’ clinical data from
hospital charts. In determining the tumor size, the
cystoscopy reports and macroscopic sizes of the
tumors present in the pathological specimens were
taken as the basis for cystectomy and TUR material,
respectively.
Pathology
Haematoxylin and eosin-stained slides from each
case were reevaluated histopathologically. All cases
were reviewed for tumor size, histologic grade,
pathologic stage, and lymphovascular invasion. For
tumor grading, according to the World Health
Organization/International Society for Urological
Pathologists (WHO/ISUP) - 1998 classification,
urothelial carcinomas were subdivided into low-grade
papillary urothelial carcinoma (LGPUC) and highgrade papillary urothelial carcinoma (HGPUC). The
TNM system was used for pathologic staging: Ta,
noninvasive papillary urothelial carcinoma; T1, tumor
has invaded subepithelial connective tissue; T2, tumor
has invaded the muscularis propria; and T3, the
tumor has invaded the perivesical tissue.
Immunohistochemistry
Expressions of CD10 were tested on formalinfixed, paraffin-embedded section from 50 urinary
bladder urothelial carcinoma tissues and 10
nonneoplastic urothelial mucosae. For the
immunohistochemical studies, immunostaining was
performed using the streptavidin-biotin-peroxidase
complex technique. Sections were placed on positively
charged glass slides, deparaffinized in xylene, and
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hydrated in graded alcohol series. They were then left
to boil in 10 mm citrate buffer saline (pH 6.0) for 20
min and washed with phosphate-buffered saline (PBS,
pH 7.3). Endogenous peroxidase activity was
quenched with 3% hydrogen peroxide. The primary
antibody used was monoclonal mouse CD10 antibody
clone 56C6 (Neomarkers, Fremont, CA, USA ) at a
1/60 dilution incubated 4 h at room temperature.
After washing in phosphate-buffered saline with
Tween-20, the tissues were incubated with a biotinconjugated secondary antibody and then incubated
using the streptavidin-biotin system for 30 min at
room temperature. The reactions became visible after
immersion of the specimens in 3,3-diaminobenzidine
tetrahydrochloride (DAB). The sections were
counterstained with Mayer’s hematoxylin stain, and
then rinsed and mounted. Appropriate positive (tonsil
tissue) and negative controls (primary antibody
omitted) were included simultaneously in the
stainings.
Evaluation of immunostaining
Immunohistochemical staining was evaluated in a
semiquantitative fashion independently by 2
pathologists (N.O.K. and B.B.), who were blinded to
the clinicopathological data. Discrepancies were
resolved by simultaneous re-examination of the slides
by both investigators using a double-headed
microscope. Membranous and cytoplasmic
membrane staining was considered positive with a 1%
cut-off point in tumor cells. The extent of
immunoreactivity was scored semiquantitatively
according to the following criteria: Negative, 1% or
fewer positive cells; 1+, 2%–10% positive cells; 2+,
11%–50% positive cells; 3+, more than 50% positive
cells.
Statistical analysis
The relationship between CD10 positivity score
and tumor size, histologic grade, pathologic stage, and
lymphovascular invasion were evaluated statistically.
The data were compiled and analyzed using SPSS,
version 13.0 (SPSS Inc., Chicago, IL, USA). Statistical
significance of the results was evaluated using chisquare tests. P values <0.05 were considered
significant.

Results
Clinicopathologic characteristics (Table 1)
The age of the patients ranged from 23 to 89 years
(mean ± SD: 67.2 ± 12.1). The subjects consisted of
46 (92%) men and 4 (8%) women. Based on
pathologic staging, 18 (36%), 17 (34%), and 15 (30%)
patients were ranked at stages pTa, pT1, and pT2,
respectively. No patients were at stage pT3. Twenty
three (46%) patients were low-grade and 27 (54%)
were high-grade. Tumor size ranged from 0.5 to 7 cm
(mean ± SD: 4.21 ± 1.54). Lymphovascular invasion
was detected in 18 (36%) cases.
Table 1. Clinic, pathologic,
characteristics.
Parameters

and

immunohistochemical

No (%)
(n = 50)

CD10 (+)
(n = 35)

46 (92%)

34 (97.1%)

4 (8%)

1 (2.9%)

Sex
Male
Female
Age
Range
Mean ± SD

23-89
67.2 ± 12.1

Tumor size
Range
Mean ± SD

0.5-7cm
4.21±1.54

Histological grade
LGPUC

23 (46%)

9 (25.7%)

HGPUC

27 (54%)

26 (74.3%)

pTa

18 (36%)

12 (34.3%)

pT1

17 (34%)

10(28.6%)

pT2

15 (30%)

13 (37.1%)

pT3

0 (0%)

0(%0)

Positive

18 (36%)

11 (31.4%)

Negative

32 (64%)

24 (68.6%)

Pathological stage

Lymphovascular invasion

LGPUC: Low- grade papillary urothelial carcinoma,
HGPUC: High- grade papillary urothelial carcinoma.
Ta: Noninvasive papillary urothelial carcinoma,
T1: Tumor has invaded subepithelial connective tissue,
T2: Tumor has invaded the muscularis propria,
T3: Tumor has invaded the perivesical tissue.
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Immunohistochemical findings
Thirty-five of the 50 (70%) patients demonstrated
positive CD10 immunostaining: +1, +2, and +3
reactivity were observed in 8 (16%), 21 (42%), and 6
(12%) tumors, respectively. The remaining 15 patients
(30%) were negative for CD10. No staining was seen
in nonneoplastic urothelium (Figure 1). Staining
pattern in positive carcinomas was diffuse
cytoplasmic in 22 patients (62.9%) and cytoplasmic
and membranous in 13 patients (37.1%) (Figure 2).
None of the cases exhibited an apical/luminal staining
pattern. HGPUCs exhibited more extensive CD10
expression than LGPUCs and this was statistically

significant (P = 0.0001) (Table 2). In 39.1% (9/23) of
the LGPUCs, positive CD10 immunoreactivity was
detected: the immunoreactivity was 1+, 2+, and 3+ in
66.7% (6/9), 33.1% (3/9), and 0% (0/9), respectively.
By contrast, a positive CD10 reaction was observed in
96.3% (26/27) of the HGPUCs, and the
immunoreactivity was 1+, 2+, and 3+ in 7.8% (2/26),
69.2% (18/26), and 23% (6/26) of these patients,
respectively. On the other hand, no significant
association between pathologic stage and CD10 score
was found (P = 0.10). CD10 expression did not differ
in terms of tumor size or presence of lymphovascular
invasion.

Figure 1. a) Nonneoplastic urothelium (Hematoxylin & Eosin [H&E], ×100), b)
Negative CD10 immunoreactivity in the nonneoplastic mucosa (Score 0;
Strept–Avidin–Biotin–Peroxidase Complex [SABC], Diaminobenzidine
[DAB], ×200), c) LGPUC (H&E, ×200), d) Focal cytoplasmic CD10
immunoreactivity in LGPUC (Score 2+; SABC, DAB, ×400), e) HGPUC (
H&E, ×100), f) Diffuse cytoplasmic and focal membranous immunoreactivity
of CD10 in HGPUC (Score 3+; SABC, DAB, ×400).

180

N. ONAK KANDEMİR, B. BAHADIR, B. DOĞAN GÜN, G. YURDAKAN, N. KARADAYI, Ş. O. ÖZDAMAR

Figure 2. Immunoreactivity of CD10 in HGPUC: a) Diffuse cytoplasmic staining (Score
3+, SABC, DAB, ×1000); b) Cytoplasmic and membranous staining (Score 3+;
SABC, DAB, ×1000).

Table 2. Extent of CD10 immunoreactivity with respect to histological grade and pathological stage of
tumors (n = 50).
Extent of CD10 immunoreactivity score
Parameters

Total
0

Histological grade
LGPUC 14 (60.9%)
HGPUC 1 (3.7%)
Total

15 (30%)

Pathological stage
pTa
6 (33.3%)
pT1
7 (41.2%)
pT2
2 (13.3%)
pT3
0 (0%)
Total

15 (30%)

1

2

3

6 (26.1%)
2 (7.4%)

3 (13%)
18 (66.7%)

0 (0%)
6 (22.2%)

23 (46%)
27 (54%)

8 (16%)

21 (42%)

6 (12%)

50 (100%)

5 (27.8%)
2 (11.8%)
1 6.7%)
0 (0%)

7 (38.9%)
6 (35.2%)
8 (53.3%)
0 (0%)

0 (0%)
2 (11.8%)
4 (26.7%)
0 (0%)

18 (36%)
17 (34%)
15 (30%)
0 (0%)

8 (16%)

21 (42%)

6 (12%)

50 (100%)

Test of. Sig.

P = 0.0001*

P = 0.10

LGPUC: Low- grade papillary urothelial carcinoma,
HGPUC: High- grade papillary urothelial carcinoma.
Ta: Noninvasive papillary urothelial carcinoma, T1: Tumour has invaded subepithelial connective tissue,
T2: Tumour has invaded the muscularis propria, T3: the tumour has invaded the perivesical tissue.
* P < .0.5 for LGPUCvs HGPUC.

Discussion
The CD10 molecule plays a role in the regulation
of cell growth, differentiation, adhesion, invasion, and
angiogenesis via enzymatic hydrolysis of various
peptide hormones (1-3). All of these processes are
important in normal physiology, as well as in tumor
growth and progression. Studies conducted on human
tumors reveal that CD10 activity exerts different
influences on different tumor types (5-9). Loss of

CD10 expression in prostate (10-11), lung (12), and
endometrial tumors (19) accelerates tumor
development and progression, and in these tumors,
CD10 is thought to function as a tumor suppressor.
In melanomas (15), breast cancers (14), and colon
(13) tumors, CD10 expression is associated with
progression and metastasis.
Few studies have investigated CD10 activity in
urinary bladder tissues, and their results have differed
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markedly. Koiso et al. detected the presence of CD10
enzyme activity and immunoreactivity in a urinary
bladder cancer cell series (18). In this study, greater
activity and expression was reported in superficial
carcinomas compared to invasive carcinomas.
McIntosh et al. developed a CD10 monoclonal
antibody appropriate for use in formalin-fixed and
paraffin-embedded human tissues (9). These
researchers investigated various normal tissues and
reported the absence of CD10 immunoreactivity in
nonneoplastic urothelium. In the same study, CD10
expression was detected in 54% of urothelial
carcinomas, but the relationship between expression
and pathologic stage or histologic grade was not
investigated. Chu et al. reported that CD10 is more
widely expressed in noninvasive urothelial
carcinomas than in invasive carcinomas (6). Murali et
al. detected CD10 expression in 50% of nonneoplastic
urinary bladder mucosa samples and in 67% of
urothelial neoplasms. They characterized CD10
expression as a parameter associated with high
histologic grade, but independent of tumor stage (17).
Bircan et al. detected CD10 expression in 9.9% of
nonneoplastic urothelium and in 43% of urothelial
tumors (16). In that study, while no relationship was
found between CD10 expression and histologic grade,
an inverse correlation was reported between CD10
expression and tumor stage.
Three different staining patterns have been
detected in various tumor types expressing CD10: an
apical/luminal CD10 staining pattern, a diffuse
cytoplasmic pattern, and a membranous/Golgi
pattern (6-7). In urothelial tumors, cytoplasmic, and
membranous patterns are more frequently observed
(6, 16-17).
Amongst studies on urothelial tissues, different
CD10 reaction patterns have been tracked, and
different limit values accepted in the scoring of CD10positivity. In some studies, only membranous staining
was recognized as significant (20), whilst most
assessed cytoplasmic, membranous and/or apical
staining patterns (9, 16-18). Whilst certain studies
classed all samples in which more than 1% of tumor
cells were stained as positive (20), most studies
required at least 10% positive cells in a sample (1617). These differences affect the positivity rate of
CD10 expression in urinary bladder tumors. In our
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study, samples in which more than 1% of tumor cells
showed cytoplasmic and/or membranous staining
were accepted as positive.
Previous studies on urothelial tumors have
reported membranous and cytoplasmic staining
patterns mostly in neoplastic or dysplastic urothelial
epithelium, however apical/luminal staining patterns
is seen more frequently in nonneoplastic urothelium
(17-18). Some investigators suggest that cytoplasmic
CD10 immunoreactivity may be an indicator of the
neoplastic alterations in urothelial epithelium. We
detected diffuse cytoplasmic reactions in 62.9% of
CD10 positive urothelial carcinomas and cytoplasmic
/membranous reactions in the remaining positive
cases. None of our cases showed purely membranous
or apical/luminal staining patterns. Our findings,
taken together with the results of previous studies,
suggest that cytoplasmic or cytoplasmic/membranous
CD10 immunoreactivity may be an indicator of
neoplastic changes in urothelial lesions.
Numerous genetic changes have been described in
urothelial tumors. Genetic aberrations on the long
arm of chromosome 3, where the CD10 gene is
located, are detected in 7–24% of invasive urothelial
carcinomas and in 1–5% of noninvasive urothelial
tumors (20-21). More genetic changes are known to
occur in high-grade tumors than in low-grade
tumors. In urothelial neoplasms CD10 expression is
reported at rates ranging from 43% to 67%. In this
study, we detected CD10 expression in 70% of
urothelial carcinomas. Similar to the findings of
Murali et al. (11), we detected more prevalent CD10
immunoreactivity in cases with high histologic grade.
This could be a consequence of genetic changes
causing wild-type or mutant CD10 expression in the
high-grade carcinomas. Our findings suggest that
CD10 expression is a parameter associated with halted
differentiation in urothelial tumors.
Various growth factors that are influential in the
pathogenesis and progression of urothelial tumors
have been described. The beginning of angiogenesis is
an important step in the transition from a superficial
papillary phenotype to that of an invasive tumor.
CD10 is known to hydrolyze endothelin, and may play
a role in urothelial tumor angiogenesis and invasion
by regulating endothelin levels (20-24). Most studies
have reported an inverse correlation between CD10
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expression and pathologic stage. Murali et al. (17),
however, have advocated that CD10 expression is a
parameter independent of stage. In the present study,
whilst CD10 expression was observed more often in
invasive tumors, a statistically significant difference
was not detected. We believe that the low number of
cases in our study may have contributed to this result.
Comprehensive studies including more cases may be
needed to clarify the effect of CD10 in the invasion
process of urothelial carcinomas.

Our findings show that urothelial carcinomas
express CD10, and that this is associated more
frequently with poorly differentiated tumor histology.
Future studies conducted in larger patient groups and
supported by additional molecular techniques should
provide the information needed to clarify the role of
CD10 expression in the pathogenesis and progression
of urothelial tumors.
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